{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T07:50:42Z","timestamp":1740124242207,"version":"3.37.3"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T00:00:00Z","timestamp":1680480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T00:00:00Z","timestamp":1680480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"DOI":"10.1007\/s11255-023-03565-6","type":"journal-article","created":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T10:01:28Z","timestamp":1680516088000},"page":"2817-2827","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["An update on d\u0131agnos\u0131s and treatment of ANCA assoc\u0131ated renal vascul\u0131t\u0131s"],"prefix":"10.1007","volume":"55","author":[{"given":"Kultigin","family":"Turkmen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9174-0351","authenticated-orcid":false,"given":"Hakan","family":"Ozer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vladimir","family":"Tesar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,4,3]]},"reference":[{"issue":"1","key":"3565_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/ART.37715","volume":"65","author":"JC Jennette","year":"2013","unstructured":"Jennette JC, Falk RJ, Bacon PA et al (2013) 2012 revised international chapel hill consensus conference nomenclature of vasculitides. Arthritis Rheum 65(1):1\u201311. https:\/\/doi.org\/10.1002\/ART.37715","journal-title":"Arthritis Rheum"},{"key":"3565_CR2","doi-asserted-by":"publisher","first-page":"102467","DOI":"10.1016\/J.JAUT.2020.102467","volume":"112","author":"Y Nguyen","year":"2020","unstructured":"Nguyen Y, Pagnoux C, Karras A et al (2020) Microscopic polyangiitis: clinical characteristics and long-term outcomes of 378 patients from the french vasculitis study group registry. J Autoimmun 112:102467. https:\/\/doi.org\/10.1016\/J.JAUT.2020.102467","journal-title":"J Autoimmun"},{"issue":"1","key":"3565_CR3","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/ART.27763","volume":"63","author":"JU Holle","year":"2011","unstructured":"Holle JU, Gross WL, Latza U et al (2011) Improved outcome in 445 patients with Wegener\u2019s granulomatosis in a German vasculitis center over four decades. Arthritis Rheum 63(1):257\u2013266. https:\/\/doi.org\/10.1002\/ART.27763","journal-title":"Arthritis Rheum"},{"key":"3565_CR4","doi-asserted-by":"publisher","DOI":"10.1007\/S40620-022-01250-Y","author":"V Tesar","year":"2022","unstructured":"Tesar V, Hruskova Z (2022) Extrarenal complications of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) and their impact on the outcome of the patients. J Nephrol. https:\/\/doi.org\/10.1007\/S40620-022-01250-Y","journal-title":"J Nephrol"},{"issue":"21","key":"3565_CR5","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1056\/NEJM199711203372106","volume":"337","author":"JC Jennette","year":"1997","unstructured":"Jennette JC, Falk RJ (1997) Small-vessel vasculitis. N Engl J Med 337(21):1512\u20131523. https:\/\/doi.org\/10.1056\/NEJM199711203372106","journal-title":"N Engl J Med"},{"issue":"6","key":"3565_CR6","doi-asserted-by":"publisher","first-page":"488","DOI":"10.7326\/0003-4819-116-6-488","volume":"116","author":"GS Hoffman","year":"1992","unstructured":"Hoffman GS, Kerr GS, Leavitt RY et al (1992) Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 116(6):488\u2013498. https:\/\/doi.org\/10.7326\/0003-4819-116-6-488","journal-title":"Ann Intern Med"},{"issue":"2","key":"3565_CR7","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/S10157-020-01978-6","volume":"25","author":"Z Aydin","year":"2021","unstructured":"Aydin Z, Turkmen K, Dede F et al (2021) Demographic, clinical and laboratory characteristics of rapidly progressive glomerulonephritis in Turkey: Turkish society of nephrology-glomerular diseases (TSN-GOLD) Working Group. Clin Exp Nephrol 25(2):173\u2013183. https:\/\/doi.org\/10.1007\/S10157-020-01978-6","journal-title":"Clin Exp Nephrol"},{"issue":"3","key":"3565_CR8","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1136\/ARD.2010.137778","volume":"70","author":"O Flossmann","year":"2011","unstructured":"Flossmann O, Berden A, De Groot K et al (2011) Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis 70(3):488\u2013494. https:\/\/doi.org\/10.1136\/ARD.2010.137778","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"3565_CR9","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1053\/J.AJKD.2019.04.031","volume":"75","author":"D Geetha","year":"2020","unstructured":"Geetha D, Jefferson JA (2020) ANCA-associated vasculitis: core curriculum. Am J Kidney Dis 75(1):124\u2013137. https:\/\/doi.org\/10.1053\/J.AJKD.2019.04.031","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"3565_CR10","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/J.KINT.2021.05.021\/ATTACHMENT\/D54815F6-C088-4C3F-A044-CFC19E0C0544\/MMC1.PDF","volume":"100","author":"BH Rovin","year":"2021","unstructured":"Rovin BH, Adler SG, Barratt J et al (2021) KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int 100(4):S1\u2013S276. https:\/\/doi.org\/10.1016\/J.KINT.2021.05.021\/ATTACHMENT\/D54815F6-C088-4C3F-A044-CFC19E0C0544\/MMC1.PDF","journal-title":"Kidney Int"},{"issue":"5","key":"3565_CR11","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1093\/NDT\/16.5.953","volume":"16","author":"K Aasar\u00f8d","year":"2001","unstructured":"Aasar\u00f8d K, Bostad L, Hammerstr\u00f8m J, J\u00f8rstad S, Iversen BM (2001) Renal histopathology and clinical course in 94 patients with Wegener\u2019s granulomatosis. Nephrol Dial Transplant 16(5):953\u2013960. https:\/\/doi.org\/10.1093\/NDT\/16.5.953","journal-title":"Nephrol Dial Transplant"},{"issue":"10","key":"3565_CR12","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1681\/ASN.2010050477","volume":"21","author":"AE Berden","year":"2010","unstructured":"Berden AE, Ferrario F, Hagen EC et al (2010) Histopathologic classification of ANCA-associated glomerulonephritis. J Am Soc Nephrol 21(10):1628\u20131636. https:\/\/doi.org\/10.1681\/ASN.2010050477","journal-title":"J Am Soc Nephrol"},{"issue":"27","key":"3565_CR13","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1056\/NEJMOA2026834","volume":"383","author":"DB Beck","year":"2020","unstructured":"Beck DB, Ferrada MA, Sikora KA et al (2020) Somatic mutations in UBA1 and severe adult-onset autoinflammatory disease. N Engl J Med 383(27):2628\u20132638. https:\/\/doi.org\/10.1056\/NEJMOA2026834","journal-title":"N Engl J Med"},{"issue":"4","key":"3565_CR14","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1002\/ART.41992","volume":"74","author":"F Muratore","year":"2022","unstructured":"Muratore F, Marvisi C, Castrignan\u00f2 P et al (2022) VEXAS syndrome: a case series from a single-center cohort of italian patients with vasculitis. Arthritis Rheumatol (Hoboken, Nj). 74(4):665. https:\/\/doi.org\/10.1002\/ART.41992","journal-title":"Arthritis Rheumatol (Hoboken, Nj)."},{"issue":"6","key":"3565_CR15","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1159\/000500352","volume":"49","author":"C Vandenbussche","year":"2019","unstructured":"Vandenbussche C, Bitton L, Bataille P et al (2019) Prognostic value of microscopic hematuria after induction of remission in antineutrophil cytoplasmic antibodies-associated vasculitis. Am J Nephrol 49(6):479\u2013486. https:\/\/doi.org\/10.1159\/000500352","journal-title":"Am J Nephrol"},{"issue":"2","key":"3565_CR16","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1002\/ART.33361","volume":"64","author":"M Walsh","year":"2012","unstructured":"Walsh M, Flossmann O, Berden A et al (2012) Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 64(2):542\u2013548. https:\/\/doi.org\/10.1002\/ART.33361","journal-title":"Arthritis Rheum"},{"issue":"10","key":"3565_CR17","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1136\/ANNRHEUMDIS-2017-211123","volume":"76","author":"A Karras","year":"2017","unstructured":"Karras A, Pagnoux C, Haubitz M et al (2017) Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis. Ann Rheum Dis 76(10):1662\u20131668. https:\/\/doi.org\/10.1136\/ANNRHEUMDIS-2017-211123","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"3565_CR18","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1136\/ARD.2007.071936","volume":"67","author":"C Mukhtyar","year":"2008","unstructured":"Mukhtyar C, Flossmann O, Hellmich B et al (2008) Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. Ann Rheum Dis 67(7):1004\u20131010. https:\/\/doi.org\/10.1136\/ARD.2007.071936","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"3565_CR19","doi-asserted-by":"publisher","first-page":"905","DOI":"10.2215\/CJN.08290813","volume":"9","author":"T Lee","year":"2014","unstructured":"Lee T, Gasim A, Derebail VK et al (2014) Predictors of treatment outcomes in ANCA-associated vasculitis with severe kidney failure. Clin J Am Soc Nephrol 9(5):905\u2013913. https:\/\/doi.org\/10.2215\/CJN.08290813","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"3565_CR20","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1093\/RHEUMATOLOGY\/KEY288","volume":"58","author":"RJ Pepper","year":"2019","unstructured":"Pepper RJ, McAdoo SP, Moran SM et al (2019) A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody-associated vasculitis. Rheumatology 58(2):260\u2013268. https:\/\/doi.org\/10.1093\/RHEUMATOLOGY\/KEY288","journal-title":"Rheumatology"},{"key":"3565_CR21","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003232.PUB3","author":"G Walters","year":"2015","unstructured":"Walters G, Willis NS, Craig JC (2015) Interventions for renal vasculitis in adults. Cochrane database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD003232.PUB3","journal-title":"Cochrane database Syst Rev"},{"issue":"3","key":"3565_CR22","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMOA0909169","volume":"363","author":"RB Jones","year":"2010","unstructured":"Jones RB, Cohen Tervaert JW, Hauser T et al (2010) Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 363(3):211\u2013220. https:\/\/doi.org\/10.1056\/NEJMOA0909169","journal-title":"N Engl J Med"},{"key":"3565_CR23","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003232.PUB4","author":"GD Walters","year":"2020","unstructured":"Walters GD, Willis NS, Cooper TE, Craig JC (2020) Interventions for renal vasculitis in adults. Cochrane database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD003232.PUB4","journal-title":"Cochrane database Syst Rev"},{"issue":"10","key":"3565_CR24","doi-asserted-by":"publisher","first-page":"670","DOI":"10.7326\/0003-4819-150-10-200905190-00004","volume":"150","author":"K Groot","year":"2009","unstructured":"Groot K, Harper L, Jayne DRW et al (2009) Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 150(10):670","journal-title":"Ann Intern Med"},{"issue":"6","key":"3565_CR25","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1093\/QJMED\/90.6.401","volume":"90","author":"D Adu","year":"1997","unstructured":"Adu D, Pall A, Luqmani RA et al (1997) Controlled trial of pulse versus continuous prednisolone and cyclophosphamide in the treatment of systemic vasculitis. QJM 90(6):401\u2013409. https:\/\/doi.org\/10.1093\/QJMED\/90.6.401","journal-title":"QJM"},{"issue":"6","key":"3565_CR26","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1136\/ANNRHEUMDIS-2015-208073","volume":"75","author":"S Unizony","year":"2016","unstructured":"Unizony S, Villarreal M, Miloslavsky EM et al (2016) Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type. Ann Rheum Dis 75(6):1166\u20131169. https:\/\/doi.org\/10.1136\/ANNRHEUMDIS-2015-208073","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"3565_CR27","doi-asserted-by":"publisher","first-page":"2688","DOI":"10.1681\/ASN.2019111197","volume":"31","author":"MC Moura","year":"2020","unstructured":"Moura MC, Irazabal MV, Eirin A et al (2020) Efficacy of rituximab and plasma exchange in antineutrophil cytoplasmic antibody-associated vasculitis with severe kidney disease. J Am Soc Nephrol 31(11):2688\u20132704. https:\/\/doi.org\/10.1681\/ASN.2019111197","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"3565_CR28","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/S41584-018-0065-X","volume":"14","author":"M McClure","year":"2018","unstructured":"McClure M, Gopaluni S, Jayne D, Jones R (2018) B cell therapy in ANCA-associated vasculitis: current and emerging treatment options. Nat Rev Rheumatol 14(10):580\u2013591. https:\/\/doi.org\/10.1038\/S41584-018-0065-X","journal-title":"Nat Rev Rheumatol"},{"issue":"8","key":"3565_CR29","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1136\/ANNRHEUMDIS-2017-212878","volume":"77","author":"P Charles","year":"2018","unstructured":"Charles P, Terrier B, Perrodeau \u00c9 et al (2018) Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2). Ann Rheum Dis 77(8):1144\u20131150. https:\/\/doi.org\/10.1136\/ANNRHEUMDIS-2017-212878","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"3565_CR30","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1136\/ANNRHEUMDIS-2019-216863","volume":"79","author":"RM Smith","year":"2020","unstructured":"Smith RM, Jones RB, Specks U et al (2020) Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis. Ann Rheum Dis 79(9):1243\u20131249. https:\/\/doi.org\/10.1136\/ANNRHEUMDIS-2019-216863","journal-title":"Ann Rheum Dis"},{"key":"3565_CR31","unstructured":"A Randomized, Controlled Trial of Rituximab versus Azathioprine After Induction of Remission with Rituximab for Patients with ANCA-associated Vasculitis and Relapsing Disease - ACR Meeting Abstracts. Accessed 16 Jan 2022"},{"issue":"7","key":"3565_CR32","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1056\/NEJMOA1803537\/SUPPL_FILE\/NEJMOA1803537_DATA-SHARING.PDF","volume":"382","author":"M Walsh","year":"2020","unstructured":"Walsh M, Merkel PA, Peh C-A et al (2020) Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N Engl J Med 382(7):622\u2013631. https:\/\/doi.org\/10.1056\/NEJMOA1803537\/SUPPL_FILE\/NEJMOA1803537_DATA-SHARING.PDF","journal-title":"N Engl J Med"},{"issue":"7","key":"3565_CR33","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.2215\/CJN.11801018\/-\/DCSUPPLEMENTAL","volume":"14","author":"J Tuin","year":"2019","unstructured":"Tuin J, Stassen PM, Bogdan DI et al (2019) Mycophenolate mofetil versus cyclophosphamide for the induction of remission in nonlife-threatening relapses of antineutrophil cytoplasmic antibody\u2013associated vasculitis: Randomized, controlled trial. Clin J Am Soc Nephrol 14(7):1021\u20131028. https:\/\/doi.org\/10.2215\/CJN.11801018\/-\/DCSUPPLEMENTAL","journal-title":"Clin J Am Soc Nephrol"},{"issue":"8","key":"3565_CR34","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1002\/ART.21142","volume":"52","author":"K De Groot","year":"2005","unstructured":"De Groot K, Rasmussen N, Bacon PA et al (2005) Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 52(8):2461\u20132469. https:\/\/doi.org\/10.1002\/ART.21142","journal-title":"Arthritis Rheum"},{"issue":"4","key":"3565_CR35","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1053\/J.AJKD.2010.10.049","volume":"57","author":"M Walsh","year":"2011","unstructured":"Walsh M, Catapano F, Szpirt W et al (2011) Plasma exchange for renal vasculitis and idiopathic rapidly progressive glomerulonephritis: a meta-analysis. Am J Kidney Dis 57(4):566\u2013574. https:\/\/doi.org\/10.1053\/J.AJKD.2010.10.049","journal-title":"Am J Kidney Dis"},{"issue":"7","key":"3565_CR36","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1681\/ASN.2007010090","volume":"18","author":"DRW Jayne","year":"2007","unstructured":"Jayne DRW, Gaskin G, Rasmussen N et al (2007) Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 18(7):2180\u20132188. https:\/\/doi.org\/10.1681\/ASN.2007010090","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"3565_CR37","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/1745-6215-14-73","volume":"14","author":"M Walsh","year":"2013","unstructured":"Walsh M, Merkel PA, Peh CA et al (2013) Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial. Trials 14(1):73. https:\/\/doi.org\/10.1186\/1745-6215-14-73","journal-title":"Trials"},{"issue":"4","key":"3565_CR38","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1111\/J.1523-1755.2004.00917.X","volume":"66","author":"JB Levy","year":"2004","unstructured":"Levy JB, Hammad T, Coulthart A, Dougan T, Pusey CD (2004) Clinical features and outcome of patients with both ANCA and anti-GBM antibodies. Kidney Int 66(4):1535\u20131540. https:\/\/doi.org\/10.1111\/J.1523-1755.2004.00917.X","journal-title":"Kidney Int"},{"issue":"7","key":"3565_CR39","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJMOA2023386\/SUPPL_FILE\/NEJMOA2023386_DATA-SHARING.PDF","volume":"384","author":"DRW Jayne","year":"2021","unstructured":"Jayne DRW, Merkel PA, Schall TJ, Bekker P (2021) Avacopan for the treatment of ANCA-associated vasculitis. N Engl J Med 384(7):599\u2013609. https:\/\/doi.org\/10.1056\/NEJMOA2023386\/SUPPL_FILE\/NEJMOA2023386_DATA-SHARING.PDF","journal-title":"N Engl J Med"},{"issue":"9","key":"3565_CR40","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.1681\/ASN.2016111179","volume":"28","author":"DRW Jayne","year":"2017","unstructured":"Jayne DRW, Bruchfeld AN, Harper L et al (2017) Randomized trial of c5a receptor inhibitor avacopan in ANCA-associated vasculitis. J Am Soc Nephrol 28(9):2756\u20132767. https:\/\/doi.org\/10.1681\/ASN.2016111179","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"3565_CR41","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1002\/acr.24634","volume":"73","author":"SA Chung","year":"2021","unstructured":"Chung SA, Langford CA, Maz M et al (2021) Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res (Hoboken) 73(8):1088\u20131105. https:\/\/doi.org\/10.1002\/acr.24634","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"8","key":"3565_CR42","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1002\/ACR.20176","volume":"62","author":"M Walsh","year":"2010","unstructured":"Walsh M, Merkel PA, Mahr A, Jayne D (2010) Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: A meta-analysis. Arthritis Care Res (Hoboken) 62(8):1166\u20131173. https:\/\/doi.org\/10.1002\/ACR.20176","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"9","key":"3565_CR43","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1093\/NDT\/GFW211","volume":"31","author":"JSF Sanders","year":"2016","unstructured":"Sanders JSF, De Joode AAE, Desevaux RG et al (2016) Extended versus standard azathioprine maintenance therapy in newly diagnosed proteinase-3 anti-neutrophil cytoplasmic antibody-associated vasculitis patients who remain cytoplasmic anti-neutrophil cytoplasmic antibody-positive after induction of remission: a randomized clinical trial. Nephrol Dial Transplant 31(9):1453\u20131459. https:\/\/doi.org\/10.1093\/NDT\/GFW211","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"3565_CR44","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1056\/NEJMOA020286","volume":"349","author":"D Jayne","year":"2003","unstructured":"Jayne D, Rasmussen N, Andrassy K et al (2003) A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 349(1):36\u201344. https:\/\/doi.org\/10.1056\/NEJMOA020286","journal-title":"N Engl J Med"},{"issue":"3","key":"3565_CR45","doi-asserted-by":"publisher","first-page":"179","DOI":"10.7326\/M19-3827","volume":"173","author":"P Charles","year":"2020","unstructured":"Charles P, Perrodeau \u00c9, Samson M et al (2020) Long-Term Rituximab Use to Maintain Remission of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Trial. Ann Intern Med 173(3):179\u2013188. https:\/\/doi.org\/10.7326\/M19-3827","journal-title":"Ann Intern Med"},{"issue":"21","key":"3565_CR46","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1001\/JAMA.2010.1658","volume":"304","author":"TF Hiemstra","year":"2010","unstructured":"Hiemstra TF, Walsh M, Mahr A et al (2010) Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. JAMA 304(21):2381\u20132388. https:\/\/doi.org\/10.1001\/JAMA.2010.1658","journal-title":"JAMA"},{"issue":"26","key":"3565_CR47","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1056\/nejmoa0802311","volume":"359","author":"C Pagnoux","year":"2008","unstructured":"Pagnoux C, Mahr A, Hamidou MA et al (2008) Azathioprine or Methotrexate Maintenance for ANCA-Associated Vasculitis. N Engl J Med 359(26):2790\u20132803. https:\/\/doi.org\/10.1056\/nejmoa0802311","journal-title":"N Engl J Med"},{"issue":"4","key":"3565_CR48","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJMOA041884","volume":"352","author":"Group TWGET","year":"2009","unstructured":"Group TWGET (2009) Etanercept plus standard therapy for wegener\u2019s granulomatosis. N Engl J Med 352(4):351\u2013361. https:\/\/doi.org\/10.1056\/NEJMOA041884","journal-title":"N Engl J Med"},{"key":"3565_CR49","unstructured":"Mikkel Faurschou, Inge Juul Sorensen, Lene Mellemkjaer, Anne Gitte Rasmussen Loft, Bjarne Svalgaard Thomsen, Niels Tvede BB. Malignancies in Wegener\u2019s granulomatosis: Incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. Accessed 16 Jan 2022."},{"issue":"4","key":"3565_CR50","doi-asserted-by":"publisher","first-page":"736","DOI":"10.2215\/CJN.07340713\/-\/DCSUPPLEMENTAL","volume":"9","author":"WF Pendergraft","year":"2014","unstructured":"Pendergraft WF, Cortazar FB, Wenger J et al (2014) Long-term maintenance therapy using rituximab-induced continuous B-cell depletion in patients with anca vasculitis. Clin J Am Soc Nephrol 9(4):736\u2013744. https:\/\/doi.org\/10.2215\/CJN.07340713\/-\/DCSUPPLEMENTAL","journal-title":"Clin J Am Soc Nephrol"},{"key":"3565_CR51","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1093\/ndt\/gfh161","volume":"19","author":"S Weidner","year":"2004","unstructured":"Weidner S, Geuss S, Hafezi-Rachti S, Wonka A, Ruprecht HD (2004) ANCA-associated vasculitis with renal involvement: an outcome analysis. Nephrol Dial Transplant 19:1403\u20131411. https:\/\/doi.org\/10.1093\/ndt\/gfh161","journal-title":"Nephrol Dial Transplant"},{"issue":"12","key":"3565_CR52","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1097\/TP.0B013E31821AB9AA","volume":"91","author":"D Geetha","year":"2011","unstructured":"Geetha D, Eirin A, True K et al (2011) Renal transplantation in antineutrophil cytoplasmic antibody-associated vasculitis: a multicenter experience. Transplantation 91(12):1370. https:\/\/doi.org\/10.1097\/TP.0B013E31821AB9AA","journal-title":"Transplantation"},{"issue":"2","key":"3565_CR53","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1159\/000505660","volume":"45","author":"Z Hruskova","year":"2020","unstructured":"Hruskova Z, Tesar V, Geetha D (2020) Renal transplantation in antineutrophil cytoplasmic antibody-associated vasculitis: current perspectives. Kidney Blood Press Res 45(2):157\u2013165. https:\/\/doi.org\/10.1159\/000505660","journal-title":"Kidney Blood Press Res"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-023-03565-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-023-03565-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-023-03565-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T19:04:33Z","timestamp":1696705473000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-023-03565-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,3]]},"references-count":53,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["3565"],"URL":"https:\/\/doi.org\/10.1007\/s11255-023-03565-6","relation":{},"ISSN":["1573-2584"],"issn-type":[{"type":"electronic","value":"1573-2584"}],"subject":[],"published":{"date-parts":[[2023,4,3]]},"assertion":[{"value":"9 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of \u0131nterest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal participants"}}]}}